פרגובריס עט מוכן להזרקה
merck serono ltd - follitropin alfa; lutropin alfa - תמיסה להזרקה - lutropin alfa 150 iu / 0.48 ml; follitropin alfa 300 iu / 0.48 ml - follitropin alfa
רביף 44 מקג
merck serono ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 88 mcg/ml - interferon beta-1a
קריסויטה 10 מג
medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 10 mg / 1 ml - burosumab
קריסויטה 20 מג
medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 20 mg / 1 ml - burosumab
קריסויטה 30 מג
medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 30 mg / 1 ml - burosumab
אספרוקט 1000 יחבל
novo nordisk ltd., israel - turoctocog alfa pegol - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa pegol 1000 iu/vial
ואביסמו
roche pharmaceuticals (israel) ltd - faricimab - תמיסה להזרקה - faricimab 120 mg/ml - faricimab
קסנפוזיים
sanofi israel ltd - olipudase alfa - olipudase alfa 20 mg/vial - olipudase alfa
נובוסבן אר.טי 1 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 2 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.